Valamor 200 mg, containing the active ingredient Ibrutinib, is a cutting-edge oral Bruton’s Tyrosine Kinase (BTK) inhibitor developed to revolutionize the treatment of various B-cell malignancies. This targeted therapy is widely prescribed for patients battling Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM). Ibrutinib, the potent component of Valamor, blocks the BTK pathway, which is crucial for B-cell cancer cell survival and proliferation.
Key Product Details:
- Active Ingredient: Ibrutinib 200 mg
- Form: Film-Coated Tablet
- Administration: Oral Use
- Packaging: 63 Film-Coated Tablets per box
- Manufacturer: Pharmanova
Benefits of Valamor 200 mg (Ibrutinib):
- Breakthrough BTK Inhibitor: Disrupts cancer cell signaling by irreversibly binding to the Bruton’s Tyrosine Kinase (BTK) enzyme.
- Extended Progression-Free Survival: Clinical trials have proven its efficacy in delaying disease progression and improving overall survival.
- Convenient Oral Therapy: Offers patients a non-invasive, easy-to-manage treatment option, eliminating the need for intravenous administration.
- High Response Rates: Achieves durable responses in both newly diagnosed and relapsed/refractory cases.
- Wide Range of Indications: Approved for CLL, SLL, MCL, and Waldenström’s Macroglobulinemia.
Indications:
- Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): First-line treatment and for relapsed or refractory cases.
- Mantle Cell Lymphoma (MCL): Recommended for patients who have received at least one prior therapy.
- Waldenström’s Macroglobulinemia (WM): A preferred therapy for this rare, slow-growing blood cancer.
How Does Valamor (Ibrutinib) Work?
Ibrutinib, a first-in-class BTK inhibitor, works by targeting and irreversibly inhibiting the Bruton’s Tyrosine Kinase enzyme. This blockade:
- Disrupts B-cell receptor (BCR) signaling.
- Inhibits cancer cell proliferation.
- Reduces cancer cell survival.
- Hinders tumor microenvironment interactions.
Dosage and Administration:
- Recommended Dose for CLL and WM: 420 mg once daily (2 x 200 mg tablets + 1 x 140 mg tablet).
- Recommended Dose for MCL: 560 mg once daily (3 x 200 mg tablets).
- Tablets should be swallowed whole with water; do not chew, crush, or split.
Safety Information:
- Common Side Effects: Diarrhea, fatigue, musculoskeletal pain, nausea, rash.
- Serious Risks: Bleeding, infections, atrial fibrillation, hypertension.
- Precautions: Patients with bleeding disorders or using anticoagulants should consult their healthcare provider.
Storage Conditions:
- Temperature: Store below 30°C in the original packaging.
- Handling: Keep away from moisture and heat.
Why Choose Valamor 200 mg (Ibrutinib)?
Valamor 200 mg offers advanced cancer care with its targeted mechanism and proven results. By precisely inhibiting BTK, it significantly reduces disease progression and enhances patients’ quality of life. Its convenient oral formulation provides flexibility and ease for patients requiring long-term treatment.
Buy Valamor 200 mg Online:
Searching for a trusted supplier to buy Valamor 200 mg (Ibrutinib Tablets) online? We guarantee genuine Pharmanova products with secure global delivery. Place your order now to access world-class treatment for B-cell malignancies.
Değerlendirmeler
Henüz değerlendirme yapılmadı.